公开(公告)号：US5133970A

公开(公告)日：1992-07-28

申请号：US550991

申请日：1990-07-11

申请人： Hans-Ulrich Petereit ,  Erna Roth

发明人： Hans-Ulrich Petereit ,  Erna Roth

IPC分类号： A61K9/70 ,  A61L15/58 ,  C08F8/44 ,  C08L33/04 ,  C08L33/06 ,  C08L33/14 ,  C09J7/02 ,  C09J133/00 ,  C09J133/04 ,  C09J133/06 ,  C09J133/14

CPC分类号： A61K9/7061 ,  A61L15/58 ,  C08F8/44 ,  C09J133/14 ,  Y10T428/31511

摘要： A water-soluble salt of a copolymer containing a monoethylenically unsaturated monomer containing amino groups that can be radically polymerized and at least one alkyl ester of acrylic and/or methacrylic acid, is used as a flexible pressure-sensitive adhesive for application to the skin.

摘要翻译： 使用含有可自由基聚合的氨基的单烯属不饱和单体和至少一种丙烯酸和/或甲基丙烯酸的烷基酯的共聚物的水溶性盐作为用于皮肤的柔性压敏粘合剂。

公开(公告)号：US4904469A

公开(公告)日：1990-02-27

申请号：US10983

申请日：1987-02-05

申请人： Hans-Ulrich Petereit ,  Gerhard Zeiss

发明人： Hans-Ulrich Petereit ,  Gerhard Zeiss

IPC分类号： A61L15/44 ,  A61L15/28 ,  A61L15/38 ,  A61L15/42

CPC分类号： A61L15/425 ,  A61L15/28 ,  A61L15/38

摘要： The invention relates to a wound covering made from a polysaccharide base, particularly cellulose, which is formed as a fabric, which has a high absorbency due to its sponge-like structure and contains non-immobilized enzymes for wound therapy.

摘要翻译： 本发明涉及由多糖基质，特别是纤维素制成的伤口覆盖物，其由织物形成，其由于其海绵状结构而具有高吸收性并且含有用于伤口治疗的非固定化酶。

公开(公告)号：US10537530B2

公开(公告)日：2020-01-21

申请号：US13603984

申请日：2012-09-05

申请人： Fang Liu ,  Abdul W. Basit ,  Rosario Lizio ,  Hans-Ulrich Petereit ,  Christian Meier ,  Michael Damm

发明人： Fang Liu ,  Abdul W. Basit ,  Rosario Lizio ,  Hans-Ulrich Petereit ,  Christian Meier ,  Michael Damm

IPC分类号： A61K9/50

摘要： The invention provides a gastric resistant, enteric-coated solid dosage form including a core containing a pharmaceutically active ingredient, an inner coating for the core, and an outer enteric coating. The inner coating comprises an anionic polymeric material or a water-soluble neutral polymeric material, and further comprises a water soluble inorganic salt which is not a carbonate or bicarbonates. The outer enteric coating comprises an anionic polymeric material which is less neutralized than the polymeric material comprising the inner coating and disintegrates rapidly at a pH of 5.5 to 7.0 upon entering the small intestine.

公开(公告)号：US09492394B2

公开(公告)日：2016-11-15

申请号：US13086079

申请日：2011-04-13

申请人： Shraddha Ashok Bodinge ,  Priyanka Bansilal Haksar ,  Seema Yashwant Gawde ,  Hemant Karbhari Pagar ,  Hans-Ulrich Petereit

发明人： Shraddha Ashok Bodinge ,  Priyanka Bansilal Haksar ,  Seema Yashwant Gawde ,  Hemant Karbhari Pagar ,  Hans-Ulrich Petereit

IPC分类号： A61K9/28

CPC分类号： A61K9/286 ,  A61K9/2846 ,  A61K9/2866

摘要： The invention relates to a gastric resistant pharmaceutical or nutraceutical composition, comprising a core, comprising a pharmaceutical or nutraceutical active ingredient and a gastric resistant coating layer onto the core, wherein the release of the pharmaceutical or nutraceutical active ingredient is not more than 15% under in-vitro conditions at pH 1.2 for 2 hours in medium according to USP with and without the addition of 40% (v/v) ethanol, wherein the gastric resistant coating layer comprises 10 to 100% by weight of one or more salts of alginic acid with a viscosity of 30 to 720 cP of a 1% aqueous solution.

摘要翻译： 本发明涉及抗胃药物或营养保健组合物，其包含核心，其包含药物或营养物质活性成分和在核心上的抗胃包衣层，其中药物或营养活性成分的释放不超过15％ 根据USP，在pH为1.2的培养基中培养2小时的体外条件，加入和不加入40％（v / v）乙醇，其中抗胃包衣层包含10至100重量％的一种或多种海藻酸盐 酸，粘度为30〜720cP的1％水溶液。

公开(公告)号：US08568778B2

公开(公告)日：2013-10-29

申请号：US11721399

申请日：2005-11-05

申请人： Rosario Lizio ,  Hans-Ulrich Petereit ,  Dave Trupti ,  Michael Gottschalk

发明人： Rosario Lizio ,  Hans-Ulrich Petereit ,  Dave Trupti ,  Michael Gottschalk

IPC分类号： A61K9/20

CPC分类号： A61K9/5138 ,  A61K9/1652 ,  A61K9/1676 ,  A61K9/1694 ,  A61K9/5192 ,  A61K31/7088

摘要： The invention relates to an oral, multiparticulate form of administration, comprising pellets in the size ranging from 50 to 2500 $g(m)m which are substantially constituted of a) an inner matrix layer containing nanoparticles that contain a nucleic acid active ingredient and being embedded in a matrix of a polymer having a mucoadhesive effect, and b) an outer film coating, substantially consisting of an anionic polymer or copolymer that is optionally formulated with pharmaceutically conventional adjuvants, especially emollients.

摘要翻译： 本发明涉及口服，多颗粒形式的施用，其包含尺寸范围为50至2500g（m）m的颗粒，其基本上由以下组成：a）含有含有核酸活性成分的纳米颗粒的内基质层， 嵌入在具有粘膜粘附作用的聚合物的基质中，以及b）外膜包衣，其基本上由阴离子聚合物或共聚物组成，其任选地与药学上常规的佐剂特别是润肤剂配制。

公开(公告)号：US20130273163A1

公开(公告)日：2013-10-17

申请号：US13648846

申请日：2012-10-10

申请人： Matthias SEILER ,  Norbert Windhab ,  Manfred Stickler ,  Hans-Ulrich Petereit

发明人： Matthias SEILER ,  Norbert Windhab ,  Manfred Stickler ,  Hans-Ulrich Petereit

IPC分类号： A61K9/14

CPC分类号： A61K9/146 ,  A61K9/1641 ,  A61K47/34 ,  A61K47/59 ,  A61K47/595 ,  A61K47/62

摘要： The invention relates to novel particulate drug-delivery systems based on a polymer support containing at least one linear, branched or cross-linked polymer in a fraction of over 50 percent by weight in relation to the total weight of the support. The system is characterised in that at least one signal substance for transport through a biological barrier and at least one active ingredient are stored, the support, signal substance and active ingredient having no covalent links and no active-ingredient specific and signal substance specific coordinative links between one another.

摘要翻译： 本发明涉及基于聚合物载体的新型颗粒药物递送系统，其包含至少一种相对于载体总重量超过50重量％的直链，支链或交联聚合物。 该系统的特征在于，存储用于传输通过生物屏障和至少一种活性成分的至少一种信号物质，所述载体，信号物质和没有共价连接并且没有活性成分特异性和信号物质特异性协调链接的信号物质和活性成分 在彼此之间

公开(公告)号：US20100291202A1

公开(公告)日：2010-11-18

申请号：US12742945

申请日：2008-02-01

申请人： Hema Ravishankar ,  Shradda Bodinge ,  Hans-Ulrich Petereit

发明人： Hema Ravishankar ,  Shradda Bodinge ,  Hans-Ulrich Petereit

IPC分类号： A61K47/32 ,  A61K9/22 ,  A61K9/52 ,  A61P43/00

CPC分类号： A61K9/5078 ,  A61K9/2081

摘要： The present invention relates to a pharmaceutical or nutraceutical preparation comprising a) a core containing a pharmaceutically or nutraceutically active substance and a substance that acts in a modulatory manner with regard of the release of pharmaceutically or nutraceutically active substances; and b) a controlling layer surrounding the core comprising i) 55 to 92% by weight based on the total weight of (meth)acrylic copolymers present in the layer of one or a mixture of a plurality of (meth)acrylate copolymers composed of 80 to 98% by weight based on the weight of the (meth)acrylic copolymer of structural units derived from C1 to C4 alkyl esters of (meth)acrylic acid and 2 to 20% by weight based on the weight of the (meth)acrylic copolymer of structural units derived from (meth)acrylate monomers with a quaternary ammonium group in the alkyl radical; and ii) 8 to 45% by weight based on the total weight of (meth)acrylic copolymers present in the layer of one or a mixture of a plurality of (meth)acrylate copolymers composed of more than 5 to 59% by weight based on the weight of the copolymer of structural units derived from acrylic acid or methacrylic acid and to tablets or capsules comprising same.

摘要翻译： 本发明涉及一种药物或营养制剂，其包含a）含有药学上或营养活性物质的核心和在释放药学或营养活性物质方面以调节方式起作用的物质; 和b）围绕芯的控制层，其包含i）55至92重量％，基于存在于由80重量份组成的多个（甲基）丙烯酸酯共聚物的一种或多种混合物的层中的（甲基）丙烯酸共聚物的总重量 至（甲基）丙烯酸共聚物的重量比为基于（甲基）丙烯酸的C1至C4烷基酯的结构单元的（甲基）丙烯酸共聚物的重量计为98重量％，基于（甲基）丙烯酸共聚物的重量为2至20重量％ 衍生自烷基中具有季铵基团的（甲基）丙烯酸酯单体的结构单元; 和ii）8至45重量％，基于存在于由多于5至59重量％组成的多个（甲基）丙烯酸酯共聚物的一种或多种（甲基）丙烯酸酯共聚物的层中的（甲基）丙烯酸共聚物）的总重量，基于 衍生自丙烯酸或甲基丙烯酸的结构单元的共聚物与包含其的片剂或胶囊的重量。

公开(公告)号：US20100247639A1

公开(公告)日：2010-09-30

申请号：US12742842

申请日：2008-02-01

申请人： Hema Ravishankar ,  Shradda Bodinge ,  Hans-Ulrich Petereit

发明人： Hema Ravishankar ,  Shradda Bodinge ,  Hans-Ulrich Petereit

IPC分类号： A61K9/00 ,  A61K9/32 ,  A61K9/48 ,  A61K31/606

CPC分类号： A23P10/30 ,  A23L27/72 ,  A61K9/5078

摘要： The present invention relates to a pharmaceutical or nutraceutical preparation comprising a) a core containing a pharmaceutically or nutraceutically active substance; and b) an inner controlling layer surrounding the core comprising i) one or a mixture of a plurality of (meth)acrylate copolymers bearing a cationic group or a group that can be converted to a cationic group; and ii) one or a mixture of a plurality of polymers or copolymers bearing an anionic group or group that can be converted to an anionic group; and c) an outer controlling layer comprising one or a mixture of a plurality of polymers or copolymers bearing an anionic group or group that can be converted to an anionic group and to tablets or capsules comprising same.

摘要翻译： 本发明涉及药物或营养制剂，其包含a）含有药学或营养活性物质的核心; 和b）围绕所述芯的内部控制层，包括i）一个或多个带有阳离子基团的甲基丙烯酸酯共聚物或可转化为阳离子基团的基团的混合物; 和ii）可以转化成阴离子基团的多个带有阴离子基团或基团的聚合物或共聚物的一种或多种混合物; 和c）包含一个或多个带有阴离子基团的聚合物或共聚物的混合物或可以转化成阴离子基团的外部控制层和包含其的片剂或胶囊的外部控制层。

公开(公告)号：US20100221324A1

公开(公告)日：2010-09-02

申请号：US12678429

申请日：2007-09-25

申请人： Hans-Ulrich Petereit ,  Hema Ravishankar ,  Ashwini Samel

发明人： Hans-Ulrich Petereit ,  Hema Ravishankar ,  Ashwini Samel

IPC分类号： A61K9/14 ,  A61K9/00 ,  A61K31/138 ,  A61K9/22 ,  A61K9/58

CPC分类号： A61K9/5078 ,  A61K9/501 ,  A61K9/5026

摘要： The invention relates to a pH-dependent controlled release pharmaceutical composition, comprising at least one pharmaceutical active ingredient, with the exception of opioids, wherein the core is coated at least by one coating layer, controlling the release of the pharmaceutical composition, wherein the coating layer comprises a polymer mixture of i) 40-95% by weight, based on dry weight of the polymer mixture, of at least one water insoluble essentially neutral vinyl polymer or copolymer, and ii) 5-60% by weight, based on dry weight of the polymer mixture, of at least one anionic polymer or copolymer, which is insoluble in a buffered medium below pH 4.0 and soluble at least in the range from pH 7.0 to pH 8.0. characterized in that the coating layer further contains 110 to 250% by weight, calculated on dry weight of the polymer mixture, of a non-porous inert lubricant and the is present in an amount of at least 60% by weight calculated on the weight of core.

摘要翻译： 本发明涉及pH依赖性控释药物组合物，其包含除阿片样物质以外的至少一种药物活性成分，其中核心至少涂覆一层涂层，以控制药物组合物的释放，其中涂层 至少一种不溶于水的基本上中性的乙烯基聚合物或共聚物，和ii）5-60重量％，基于干燥的聚合物混合物，i）40-95重量％，基于聚合物混合物的干重， 聚合物混合物的至少一种阴离子聚合物或共聚物的重量，其不溶于低于pH 4.0的缓冲介质并且可溶于至少在7.0至8.0的范围内。 其特征在于，所述涂层还包含110-250重量％，以聚合物混合物的干重计算的非多孔惰性润滑剂，并且其含量以至少60重量％的量存在，以重量计 核心。

公开(公告)号：US20090041842A1

公开(公告)日：2009-02-12

申请号：US11815632

申请日：2005-12-15

申请人： Rosario Lizio ,  Hans-Ulrich Petereit ,  Erna Roth ,  Michael Damm ,  Ruediger Alexowsky

发明人： Rosario Lizio ,  Hans-Ulrich Petereit ,  Erna Roth ,  Michael Damm ,  Ruediger Alexowsky

IPC分类号： A61K9/16 ,  C08L33/08 ,  A61K9/20 ,  A61K47/32

CPC分类号： C08F220/18 ,  A61K9/2846 ,  A61K9/5026

摘要： The invention relates to a partly neutralised anionic (meth)acrylate copolymer consisting of radically polymerised units containing 25-95% by weight (meth)acrylic acid C1 to C4 alkylesters and 5-75% by weight (meth)acrylate monomer with an anionic group, wherein 0.1 to 25% contained anionic groups are neutralised by a base. Said invention is characterised in that said base is embodied in the form of an cationic organic base whose molecular weight is greater than 150. A medical form containing said partly neutralised anionic (meth)acrylate copolymer and the use of said partly neutralised anionic (meth)acrylate copolymer for producing a medical form rapidly releasing an active substance having a determined pH value are also disclosed.

摘要翻译： 本发明涉及部分中和的阴离子（甲基）丙烯酸酯共聚物，其由含有25-95重量％（甲基）丙烯酸C1至C4烷基酯和5-75重量％（甲基）丙烯酸酯单体的自由基聚合单元组成，具有阴离子基团 ，其中0.1〜25％的阴离子基团被碱中和。 所述发明的特征在于所述碱以分子量大于150的阳离子有机碱的形式实施。含有所述部分中和的阴离子（甲基）丙烯酸酯共聚物的医用形式以及所述部分中和的阴离子（甲基）丙烯酸酯共聚物的用途， 丙烯酸酯共聚物，用于制备快速释放具有确定的pH值的活性物质的医用形式。